A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 - A single institution experience

Metintas M., Ak G., Erginel S., Alatas F., Yildirim H., Kurt E., ...More

LUNG CANCER, vol.55, no.3, pp.379-387, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55 Issue: 3
  • Publication Date: 2007
  • Doi Number: 10.1016/j.lungcan.2006.11.005
  • Journal Name: LUNG CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.379-387
  • Keywords: mesothelioma, therapy, chemotherapy, best supportive care, prognosis, MULTIMODALITY THERAPY, EUROPEAN-ORGANIZATION, PROGNOSTIC-FACTORS, CANCER-INSTITUTE, PHASE-III, CISPLATIN, COMBINATION, OXALIPLATIN, MITOMYCIN
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

The aim of this study was to investigate the efficacy and safety profile of chemotherapy (CT) compared to best supportive care (BSC) in patients with histopathologically confirmed diffuse malignant pleural mesothelioma (DMPM). A total of 161 patients between 1990 and 2004 treated either with CT (109 patients) or BSC (52 patients) depending on patients choice were evaluated in this analyses. Chemotherapy protocols included a combination of cisplatin, mitomycin C and recombinant interferon alpha 2a (CM-In), or cisplatin, mitomycin C and ifosfamide (CMI), or cisplatin and gemcitabine (CG).